# del(17p) / TP53 aberration in CLL

Source: https://onco.cc/terms/del17p-tp53/  
OnCo record `del17p-tp53` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A del(17p) deletion or TP53 mutation means loss or damage of the p53 safety gene in CLL. These patients should never get chemotherapy; they need BTK inhibitors or venetoclax, usually continuously.

## Summary

Present in ~5-10% at diagnosis and up to 40% at relapse. Chemoimmunotherapy is ineffective; continuous BTK inhibition (SEQUOIA arm C, 5-year PFS 72% with zanubrutinib) or venetoclax-based therapy is standard; fixed-duration regimens have shorter remissions in this group. Excluded from AMPLIFY, so acalabrutinib-venetoclax is not labelled for del(17p)/TP53.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia
- ClinicalTrials.gov NCT03336333: SEQUOIA: https://clinicaltrials.gov/study/NCT03336333
- ClinicalTrials.gov NCT03836261: AMPLIFY: https://clinicaltrials.gov/study/NCT03836261

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic lymphocytic leukaemia, first treatment](https://onco.cc/cancers/cll-treatment-naive/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/), [Richter transformation of chronic lymphocytic leukaemia](https://onco.cc/cancers/richter-transformation-cll/)
- technologies: [Cytogenetics and FISH](https://onco.cc/technologies/cytogenetics-fish/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- trials: [AMPLIFY](https://onco.cc/trials/amplify/), [SEQUOIA](https://onco.cc/trials/sequoia/)
- pairings: [Caution: chemoimmunotherapy in del(17p)/TP53 CLL](https://onco.cc/pairings/cit-in-del17p-caution/)
- key papers: [AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients](https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/), [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/), [MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL](https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/)
- terms: [CLL-IPI (chronic lymphocytic leukaemia prognostic index)](https://onco.cc/terms/cll-ipi/)
- pathways: [The p53 network (guardian of the genome)](https://onco.cc/pathways/p53-mdm2-axis/)
- biomarkers: [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)

---
JSON: https://onco.cc/api/v1/entities/del17p-tp53.json